Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes

被引：0
|
作者：
Basho, Reva K.
Trevarton, Alex
Hess, Kenneth R.
Fu, Chunxiao
Lau, Rosanna
Lin, Chih-Hsu
Lichtarge, Olivier
Yang, Wei Tse
Symmans, William Fraser
Moulder, Stacy L.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
    不详
    BIOSCIENCE REPORTS, 2024, 44 (07)
  • [22] Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple-negative breast cancer
    Solzak, Jeffrey P.
    Atale, Rutuja
    Hancock, Brad
    Radovich, Milan
    CANCER RESEARCH, 2015, 75
  • [23] Ultrasound assessment of residual disease after neoadjuvant chemotherapy (NACT) in node positive triple negative breast cancer (TNBC)
    Adrada, B. E.
    Valero, V.
    Reddy, S. M.
    Barcenas, C. H.
    Candelaria, R.
    Wei, W.
    Rauch, G. M.
    CANCER RESEARCH, 2019, 79 (04)
  • [24] Erianin induces triple-negative breast cancer cells apoptosis by activating PI3K/Akt pathway
    Xu, Yonggang
    Fang, Rong
    Shao, Jie
    Cai, Zihao
    BIOSCIENCE REPORTS, 2021, 41 (04)
  • [25] PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer
    Altundag, Kadri
    MEDICAL ONCOLOGY, 2024, 41 (11)
  • [26] Real-world data (RWD) from patients with triple-negative breast cancer (TNBC) receiving pembrolizumab with neoadjuvant chemotherapy (NACT plus P) versus NACT alone
    Mckeon, J.
    Daniels, E.
    Gibbs, L.
    Comins, C.
    Jenkins, J.
    Strawson-Smith, T.
    Mohan, V.
    Allah, M. H.
    Braybrooke, J.
    Robinson, T.
    CLINICAL ONCOLOGY, 2025, 38
  • [27] Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
    Lehmann, Brian D.
    Jovanovic, Bojana
    Chen, Xi
    Estrada, Monica V.
    Johnson, Kimberly N.
    Shyr, Yu
    Moses, Harold L.
    Sanders, Melinda E.
    Pietenpol, Jennifer A.
    PLOS ONE, 2016, 11 (06):
  • [28] Incidence and histological subtypes of triple-negative breast cancer
    Marian, C.
    Boros, M.
    Podeanu, M. D.
    Stolnicu, S.
    VIRCHOWS ARCHIV, 2011, 459 : S84 - S84
  • [29] Impact of weight change during neoadjuvant chemotherapy on pathologic response in triple-negative breast cancer
    Bao, Jean
    Borja, Nicholas
    Rao, Madhu
    Huth, James
    Leitch, A. Marilyn
    Rivers, Aeisha
    Wooldridge, Rachel
    Rao, Roshni
    CANCER MEDICINE, 2015, 4 (04): : 500 - 506
  • [30] Impact of Weight Change During Neoadjuvant Chemotherapy on Pathologic Response in Triple-Negative Breast Cancer
    Bao, Jean
    Wooldridge, Rachel
    Rivers, Aeisha
    Huth, James
    Leitch, Marilyn
    Rao, Roshni
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 27 - 28
12345